TCM

TCG Crossover Management Portfolio holdings

AUM $2.03B
1-Year Est. Return 373.29%
This Quarter Est. Return
1 Year Est. Return
+373.29%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$876M
AUM Growth
+$142M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
40
New
Increased
Reduced
Closed

Top Buys

1
+$23.2M
2
+$10.6M
3
+$9.99M

Top Sells

1
+$39.2M
2
+$11M
3
+$7.44M
4
KURA icon
Kura Oncology
KURA
+$3.97M
5
THRD
Third Harmonic Bio
THRD
+$3.2M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
26
Enliven Therapeutics
ELVN
$1.55B
$9.99M 1.14%
+498,000
MBX
27
MBX Biosciences
MBX
$1.93B
$7.42M 0.85%
650,000
NKTR icon
28
Nektar Therapeutics
NKTR
$734M
$6.89M 0.79%
266,666
-1
VTGN icon
29
VistaGen Therapeutics
VTGN
$26.5M
$5.35M 0.61%
2,676,580
KOD icon
30
Kodiak Sciences
KOD
$1.63B
$4.27M 0.49%
1,145,538
KURA icon
31
Kura Oncology
KURA
$775M
$4.24M 0.48%
735,184
-688,458
TRDA icon
32
Entrada Therapeutics
TRDA
$404M
$3.93M 0.45%
584,955
ADVM
33
DELISTED
Adverum Biotechnologies
ADVM
$3.86M 0.44%
1,796,482
AVTX icon
34
Avalo Therapeutics
AVTX
$300M
$2.41M 0.28%
483,000
VTYX icon
35
Ventyx Biosciences
VTYX
$994M
$677K 0.08%
316,195
JBIO
36
Jade Biosciences
JBIO
$723M
$640K 0.07%
64,023
CABA icon
37
Cabaletta Bio
CABA
$200M
$132K 0.02%
86,795
CMPS
38
Compass Pathways
CMPS
$733M
– –
-3,858,000
KROS icon
39
Keros Therapeutics
KROS
$595M
– –
0
MLYS icon
40
Mineralys Therapeutics
MLYS
$2.64B
– –
-2,470,265
1
2